[{"id":"programmable-dna-targeting-therapeutics","kind":"technology","name":"Programmable DNA-targeting therapeutics","route":"/technologies/programmable-dna-targeting-therapeutics/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/frontier.ts","type":"changed","fields":[{"field":"tldr","before":"\"An experimental idea: a drug that reads a cell's DNA, recognises a cancer-specific sequence, and kills only cells that carry it. Change the guide, and the same drug becomes a new drug.\"","after":"\"Programmable DNA-targeting therapeutics are an experimental idea: a drug that reads a cell's DNA, recognises a cancer-specific sequence, and kills only cells that carry it. Change the guide, and the same drug becomes..."},{"field":"summary","before":"\"Sequence-programmable therapeutics aim to act at the DNA level rather than the protein level, in principle reaching drivers with no druggable protein pocket (MYC, TP53 loss, APC loss). Conceptual relatives include CR...","after":"\"Sequence-programmable therapeutics aim to act at the DNA level rather than the protein level, in principle reaching drivers with no druggable protein pocket (MYC, TP53 loss, APC loss). Conceptual relatives include CR..."},{"field":"limitations","before":"[\"No human data as of 2026\", \"Delivery to solid tumours is unsolved for nucleic-acid therapeutics\", \"Off-target cutting or recognition; immunogenicity of bacterial proteins\", \"Tumour heterogeneity means a single seque...","after":"[\"No human data yet (2026)\", \"Delivery to solid tumours is unsolved for nucleic-acid therapeutics\", \"Off-target cutting or recognition; immunogenicity of bacterial proteins\", \"Tumour heterogeneity means a single seque..."}]},{"id":"programmable-dna-targeting-therapeutics","kind":"technology","name":"Programmable DNA-targeting therapeutics","route":"/technologies/programmable-dna-targeting-therapeutics/","commit":"335b83f6e7","date":"2026-09-06","author":"Jude Gomila","message":"Expand companies: Katsutake map imports and 44 frontier oncology companies; add frontier technologies (programmable DNA-targeting, fragmento","file":"src/data/frontier.ts","type":"added","fields":[{"field":"id"},{"field":"kind"},{"field":"name"},{"field":"sections"},{"field":"status"},{"field":"asOf"},{"field":"tldr"},{"field":"summary"},{"field":"principle"},{"field":"strengths"},{"field":"limitations"},{"field":"technologies"},{"field":"targets"},{"field":"tags"},{"field":"links"}]}]